JMP Securities Reaffirms “Market Outperform” Rating for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “market outperform” rating reissued by investment analysts at JMP Securities in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $18.00 target price on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. HC Wainwright lowered their price objective on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating for the company in a research note on Monday, November 18th. Royal Bank of Canada decreased their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, November 15th. Finally, Oppenheimer cut their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $12.80.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO opened at $1.98 on Friday. Inovio Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $14.75. The company’s 50 day moving average price is $3.42 and its 200-day moving average price is $6.10. The company has a market capitalization of $51.68 million, a P/E ratio of -0.95 and a beta of 0.84.

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of INO. BNP Paribas Financial Markets lifted its position in shares of Inovio Pharmaceuticals by 177.0% during the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 3,630 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Inovio Pharmaceuticals in the 3rd quarter worth approximately $71,000. The Manufacturers Life Insurance Company bought a new position in shares of Inovio Pharmaceuticals in the second quarter valued at approximately $82,000. MetLife Investment Management LLC increased its position in shares of Inovio Pharmaceuticals by 129.1% during the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 8,546 shares during the last quarter. Finally, Atom Investors LP bought a new stake in Inovio Pharmaceuticals during the third quarter worth $103,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.